Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jul;7(7):1846–1850. doi: 10.1158/1535-7163.MCT-08-0168

Figure 1.

Figure 1

BT-474 and SK-BR-3 cells are sensitive to lapatinib. A, BT-474 and SK-BR-3 cells were treated with 0 (vehicle), 0.1, or 1 μmol/L lapatinib for 24 h. Western blot analysis was done to detect phosphorylated EGFR (Y1173), HER2 (Y1248), Akt (S473), extracellular signal-regulated kinase1/2 (p-ERK; T202/Y204), and p27. β-actin was used as a loading control. B, BT-474 and SK-BR-3 cells were plated in 96-well plates and treated with 10-fold serial dilutions of lapatinib ranging from 0.001 to 1 μmol/L for 72 h. The percentage cell viability was evaluated by WST-1 assay. Each experiment was repeated thrice independently.

HHS Vulnerability Disclosure